RT Journal Article
SR Electronic
T1 Cyclosporine and organ transplantation
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 263
OP 270
VO 52
IS 2
A2 Donald G. Vidt
A2 Alan W. Bakst
A1 Donald R. Steinmuller
YR 1985
UL http://www.ccjm.org/content/52/2/263.abstract
AB Cyclosporine is a potent new immunosuppressive agent which is now available for use in clinical transplantation. It has a unique mechanism of action, interfering primarily with the cell-mediated response to foreign antigens. Cyclosporine has been very effective in preventing early graft loss due to rejection and has resulted in improved graft survival following kidney, heart, and liver transplants. Its major disadvantage is nephrotoxicity, which may be early (due to synergistic effects with other problems such as ischemic renal failure) or long-term (interstitial fibrosis and tubular atrophy). As cyclosporine is used more effectively, graft survival may be improved with minimal risk of toxicity.